vs
Healthpeak Properties（DOC）とIdexx Laboratories（IDXX）の財務データ比較。上の社名をクリックして会社を切り替えられます
Idexx Laboratoriesの直近四半期売上が大きい（$1.1B vs $702.9M、Healthpeak Propertiesの約1.6倍）。Healthpeak Propertiesの純利益率が高く（51.6% vs 22.8%、差は28.9%）。Idexx Laboratoriesの前年同期比売上増加率が高い（14.3% vs -6.6%）。過去8四半期でIdexx Laboratoriesの売上複合成長率が高い（6.4% vs 0.5%）
ヘルスピーク・プロパティーズ社は米国の不動産投資信託（REIT）で、高齢者住宅、ライフサイエンス関連施設、医療事務所といったヘルスケア業界関連の不動産を主な投資対象としている。2007年にメリーランド州で設立され、本社をコロラド州デンバーに置き、アーバイン、ナッシュビル、サンフランシスコにも拠点を持つ。2019年12月31日時点で617物件の権益を保有している。
IDEXXラボラトリーズは1983年設立の米国多国籍企業で、伴侶動物獣医療、家畜・家禽、水質検査、乳製品分野向けの製品・サービスの開発・製造・流通を手がけています。本社はメイン州ウェストブルックにあり、EMEA地域の拠点はオランダのホーフドルプに置かれています。
DOC vs IDXX — 直接比較
損益計算書 — Q1 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $702.9M | $1.1B |
| 純利益 | $363.0M | $248.2M |
| 粗利率 | — | 60.3% |
| 営業利益率 | 0.7% | 28.9% |
| 純利益率 | 51.6% | 22.8% |
| 売上前年比 | -6.6% | 14.3% |
| 純利益前年比 | 28.3% | 14.8% |
| EPS（希薄化後） | $0.28 | $3.09 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | $702.9M | — | ||
| Q4 25 | $719.4M | $1.1B | ||
| Q3 25 | $705.9M | $1.1B | ||
| Q2 25 | $694.3M | $1.1B | ||
| Q1 25 | $702.9M | $998.4M | ||
| Q4 24 | $698.0M | $954.3M | ||
| Q3 24 | $700.4M | $975.5M | ||
| Q2 24 | $695.5M | $1.0B |
| Q1 26 | $363.0M | — | ||
| Q4 25 | $114.0M | $248.2M | ||
| Q3 25 | $-117.1M | $274.6M | ||
| Q2 25 | $31.7M | $294.0M | ||
| Q1 25 | $42.8M | $242.7M | ||
| Q4 24 | $4.5M | $216.1M | ||
| Q3 24 | $85.9M | $232.8M | ||
| Q2 24 | $146.0M | $203.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 60.3% | ||
| Q3 25 | 58.6% | 61.8% | ||
| Q2 25 | 60.2% | 62.6% | ||
| Q1 25 | 61.1% | 62.4% | ||
| Q4 24 | 60.3% | 59.8% | ||
| Q3 24 | 60.0% | 61.1% | ||
| Q2 24 | 60.6% | 61.7% |
| Q1 26 | 0.7% | — | ||
| Q4 25 | 17.4% | 28.9% | ||
| Q3 25 | 9.2% | 32.1% | ||
| Q2 25 | 5.7% | 33.6% | ||
| Q1 25 | 7.7% | 31.7% | ||
| Q4 24 | -2.2% | 27.4% | ||
| Q3 24 | 14.1% | 31.2% | ||
| Q2 24 | 22.3% | 26.3% |
| Q1 26 | 51.6% | — | ||
| Q4 25 | 73.2% | 22.8% | ||
| Q3 25 | -16.6% | 24.8% | ||
| Q2 25 | 4.6% | 26.5% | ||
| Q1 25 | 6.1% | 24.3% | ||
| Q4 24 | 0.7% | 22.7% | ||
| Q3 24 | 12.3% | 23.9% | ||
| Q2 24 | 21.0% | 20.3% |
| Q1 26 | $0.28 | — | ||
| Q4 25 | $0.16 | $3.09 | ||
| Q3 25 | $-0.17 | $3.40 | ||
| Q2 25 | $0.05 | $3.63 | ||
| Q1 25 | $0.06 | $2.96 | ||
| Q4 24 | $0.02 | $2.62 | ||
| Q3 24 | $0.12 | $2.80 | ||
| Q2 24 | $0.21 | $2.44 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $-1.2B | $180.1M |
| 総負債低いほど良い | — | $450.0M |
| 株主資本純資産 | $7.8B | $1.6B |
| 総資産 | $21.6B | $3.4B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.28× |
8四半期トレンド — 暦四半期で整列
| Q1 26 | $-1.2B | — | ||
| Q4 25 | $467.5M | $180.1M | ||
| Q3 25 | $91.0M | $208.2M | ||
| Q2 25 | $89.4M | $164.6M | ||
| Q1 25 | $70.6M | $164.0M | ||
| Q4 24 | $119.8M | $288.3M | ||
| Q3 24 | $180.4M | $308.6M | ||
| Q2 24 | $106.9M | $401.6M |
| Q1 26 | — | — | ||
| Q4 25 | $9.8B | $450.0M | ||
| Q3 25 | $9.1B | — | ||
| Q2 25 | $9.0B | — | ||
| Q1 25 | $8.9B | — | ||
| Q4 24 | $8.7B | $617.8M | ||
| Q3 24 | $8.6B | — | ||
| Q2 24 | $8.6B | — |
| Q1 26 | $7.8B | — | ||
| Q4 25 | $7.5B | $1.6B | ||
| Q3 25 | $7.6B | $1.6B | ||
| Q2 25 | $7.9B | $1.5B | ||
| Q1 25 | $8.2B | $1.4B | ||
| Q4 24 | $8.4B | $1.6B | ||
| Q3 24 | $8.6B | $1.6B | ||
| Q2 24 | $8.8B | $1.6B |
| Q1 26 | $21.6B | — | ||
| Q4 25 | $20.3B | $3.4B | ||
| Q3 25 | $19.6B | $3.4B | ||
| Q2 25 | $19.8B | $3.3B | ||
| Q1 25 | $19.8B | $3.2B | ||
| Q4 24 | $19.9B | $3.3B | ||
| Q3 24 | $20.0B | $3.4B | ||
| Q2 24 | $20.2B | $3.4B |
| Q1 26 | — | — | ||
| Q4 25 | 1.31× | 0.28× | ||
| Q3 25 | 1.20× | — | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 1.04× | 0.39× | ||
| Q3 24 | 1.00× | — | ||
| Q2 24 | 0.98× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | — | $355.8M |
| フリーキャッシュフロー営業CF - 設備投資 | — | $326.3M |
| FCFマージンFCF / 売上 | — | 29.9% |
| 設備投資強度設備投資 / 売上 | 3.4% | 2.7% |
| キャッシュ転換率営業CF / 純利益 | — | 1.43× |
| 直近12ヶ月FCF直近4四半期 | — | $1.1B |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | — | ||
| Q4 25 | $1.3B | $355.8M | ||
| Q3 25 | $315.0M | $402.3M | ||
| Q2 25 | $363.5M | $185.7M | ||
| Q1 25 | $279.4M | $238.0M | ||
| Q4 24 | $1.1B | $262.0M | ||
| Q3 24 | $318.2M | $220.1M | ||
| Q2 24 | $316.2M | $248.3M |
| Q1 26 | — | — | ||
| Q4 25 | $357.0M | $326.3M | ||
| Q3 25 | — | $371.2M | ||
| Q2 25 | — | $151.6M | ||
| Q1 25 | — | $207.9M | ||
| Q4 24 | $333.7M | $232.8M | ||
| Q3 24 | — | $192.0M | ||
| Q2 24 | — | $215.0M |
| Q1 26 | — | — | ||
| Q4 25 | 49.6% | 29.9% | ||
| Q3 25 | — | 33.6% | ||
| Q2 25 | — | 13.7% | ||
| Q1 25 | — | 20.8% | ||
| Q4 24 | 47.8% | 24.4% | ||
| Q3 24 | — | 19.7% | ||
| Q2 24 | — | 21.4% |
| Q1 26 | 3.4% | — | ||
| Q4 25 | 124.4% | 2.7% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 3.1% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | 105.6% | 3.1% | ||
| Q3 24 | — | 2.9% | ||
| Q2 24 | — | 3.3% |
| Q1 26 | — | — | ||
| Q4 25 | 10.99× | 1.43× | ||
| Q3 25 | — | 1.47× | ||
| Q2 25 | 11.48× | 0.63× | ||
| Q1 25 | 6.52× | 0.98× | ||
| Q4 24 | 235.43× | 1.21× | ||
| Q3 24 | 3.71× | 0.95× | ||
| Q2 24 | 2.17× | 1.22× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
DOC
| Outpatient Medical | $320.5M | 46% |
| Lab | $217.6M | 31% |
| Senior Housing | $148.9M | 21% |
| Other | $14.3M | 2% |
| Corporate Non-segment | $1.5M | 0% |
IDXX
| Vet Lab Consumables | $389.0M | 36% |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | 32% |
| Rapid Assay Products | $76.0M | 7% |
| Recurring Revenue | $70.6M | 6% |
| CAG Diagnostic Capital Instruments | $58.1M | 5% |
| Water Segment | $50.5M | 5% |
| Livestock And Poultry Diagnostics Segment | $37.5M | 3% |
| CAG Diagnostics Service And Accessories | $35.3M | 3% |
| Systems And Hardware | $20.1M | 2% |
| Rebate And Up Front Considerations Arrangements | $2.4M | 0% |
| Extended Warranties And Post Contract Support Revenue | $1.0M | 0% |
